1. Effects of interventions.
| Indication | Prolonged fever and neutropenia (suspected IFI) |
Candidaemia / Invasive Candidiasis (proven IFI) |
||
| Comparisons | 1. Lipid preparations of amphotericin B compared with conventional amphotericin B | 2. Echinocandin compared with lipid preparations of amphotericin B | 3. Echinocandin compared with lipid preparations of amphotericin B | 4. Fluconazole compared with itraconazole |
| 1. Mortality (all cause) | RR = 0.73 (95% CI 0.17 to 3.11), P = 0.67 (Analysis 1.1) | ‐ | RR = 1.05 (95% CI 0.53 to 2.02), P = 0.91 (Analysis 3.1) | RR = 0.52 (95% CI 0.11 to 2.56), P = 0.42 (Analysis 4.1) |
| 2. Mortality (related to fungal infection) | RR = 0.20 (95% CI 0.01 to 3.98), P = 0.29 (Analysis 1.2) | ‐ | RR = 1.38 (95% CI 0.33 to 5.89), P = 0.66 (Analysis 3.2) | RR = 1.05 (95% CI 0.07 to 15.69), P = 0.97). (Analysis 4.2) |
| 3. Complete resolution of fungal infection | RR = 1.50 (95% CI 0.18 to 12.46), P = 0.71 (Analysis 1.3) | ‐ | RR = 0.88 (95% CI 0.68 to 1.13), P = 0.49 (Analysis 3.3) | RR = 0.99 (95% CI 0.74 to 1.32), P = 0.94 (Analysis 4.3) |
| 4. Partial resolution of fungal infection | ‐ | ‐ | ‐ | ‐ |
| 5. Resolution of fever in suspected fungal infection | RR = 1.23 (95% CI 1.00 to 1.52), P = 0.05, I 2= 0% (Analysis 1.5) | RR = 1.34 (95% CI 0.70 to 2.56), P = 0.38. (Analysis 2.5) | ‐ | ‐ |
| 6. Progression of disease requiring change or addition of an antifungal agent | ‐ | ‐ | ‐ | ‐ |
| 7. Breakthrough fungal infection requiring change or addition of an antifungal agent | RR = 0.67 (95% CI 0.24 to 1.84), P = 0.43, I2 = 0% (Analysis 1.7) | RR = 0.15 (95% CI 0.01 to 3.61), P = 0.24 (Analysis 2.7) | ‐ | ‐ |
| 8. Any clinically significant adverse reactions attributed to the antifungal agent resulting in discontinuation, dose reduction or change in the therapy | ‐ | ‐ | RR = 0.35 (95% CI 0.04 to 3.22), P = 0.35 (Analysis 3.8) | ‐ |
| 9. Any adverse reactions attributed to the antifungal agent (total) | RR = 0.49 (95% CI 0.21 to 1.17), P = 0.11, I2 = 86% (Analysis 1.9) | ‐ | RR = 0.86 (95% CI 0.53 to 1.38), P = 0.53 (Analysis 3.9) | ‐ |
| 9a. Abnormal renal function | RR = 0.43 (95% CI 0.21 to 0.90), P = 0.02, I2 = 59% (Analysis 1.10) | ‐ | ‐ | RR = 0.71 (95% CI 0.13 to 3.72), P = 0.68 (Analysis 4.10) |
| 9b. Electrolyte imbalance such as hypokalaemia | RR = 0.71 (95% CI 0.45 to 1.14), P = 0.16, I2 = 54% (Analysis 1.11) | ‐ | RR = 0.47 (95% CI 0.18 to 1.27), P = 0.14 (Analysis 3.11) | RR = 1.06 [95% CI 0.25 to 4.54], P = 0.94 (Analysis 4.11) |
| 9c. Abnormal hepatic function | RR = 1.12 (95% CI 0.74 to 1.71), P = 0.59, I2= 0% (Analysis 1.12) | ‐ | RR = 1.93 (95% CI 0.19 to 20.12), P = 0.58 (Analysis 3.12) | RR = 1.06 (95% CI 0.07 to 15.62), P = 0.97 (Analysis 4.12) |
| 9d. Infusion‐related reactions such as chills, rigors or anaphylaxis | see text; Effects of interventions | ‐ | RR = 0.73 (95% CI 0.30 to 1.77), P = 0.48 (Analysis 3.13) | ‐ |
| 9e. Gastrointestinal disturbances such as nausea, vomiting or diarrhoea | ‐ | ‐ | Vomiting: RR = 1.19 (95% CI 0.46 to 3.04), P = 0.72 (Analysis 3.14) Diarrhoea: RR = 0.83 (95% CI 0.24 to 2.92), P = 0.77 (Analysis 3.14) |
‐ |
| 9f. Neurological disturbances such as blurred vision or dizziness | ‐ | ‐ | ‐ | ‐ |
| 9g. Haematological disturbances such as anaemia, granulocytopaenia or thrombocytopaenia | ‐ | ‐ | RR = 1.56 (95% CI 0.60 to 4.07), P = 0.37 (Analysis 3.16) | ‐ |
| 10. Length of stay | ‐ | ‐ | ‐ | ‐ |
| 11. Quality of life | ‐ | ‐ | ‐ | ‐ |
| 12. Cost | ‐ | ‐ | ‐ | ‐ |